Phathom Pharmaceuticals (PHAT) EPS (Weighted Average and Diluted) (2021 - 2026)
Phathom Pharmaceuticals (PHAT) reported EPS (Weighted Average and Diluted) of -$0.37 for Q1 2026, up 71.76% year-over-year from -$0.22 in Q1 2025, and down 37.04% quarter-over-quarter from -$0.27 in Q4 2025.
Phathom Pharmaceuticals (PHAT) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.37 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.37, up 71.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 (up 59.54% YoY), and the FY2025 annual result was -$3.03, up 42.72% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.37 in Q1 2026 per PHAT's latest filing, from -$0.27 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.27 in Q4 2025 and troughed at -$1.56 in Q2 2024.
- A 5-year average of -$1.04 and a median of -$1.07 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) plunged 85.71% in 2024, then soared 73.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.33 in 2022, then retreated by 9.02% to -$1.45 in 2023, then jumped by 31.03% to -$1.0 in 2024, then soared by 73.0% to -$0.27 in 2025, then sank by 37.04% to -$0.37 in 2026.
- Business Quant data shows PHAT's EPS (Weighted Average and Diluted) at -$0.37 in Q1 2026, -$0.27 in Q4 2025, and -$0.41 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -0.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.37 |
| Dec 31, 2025 | -0.27 |
| Sep 30, 2025 | -0.41 |
| Jun 30, 2025 | -1.05 |
| Mar 31, 2025 | -1.31 |
| Dec 31, 2024 | -1.00 |
| Sep 30, 2024 | -1.32 |
| Jun 30, 2024 | -1.56 |
| Mar 31, 2024 | -1.42 |
| Dec 31, 2023 | -1.45 |
| Sep 30, 2023 | -0.76 |
| Jun 30, 2023 | -0.84 |
| Mar 31, 2023 | -0.89 |
| Dec 31, 2022 | -1.33 |
| Sep 30, 2022 | -1.32 |
| Jun 30, 2022 | -1.33 |
| Mar 31, 2022 | -1.07 |
| Dec 31, 2021 | -0.95 |
| Sep 30, 2021 | -0.98 |
| Jun 30, 2021 | -1.00 |